The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), persists principally in B cells of its host. We constructed recombinant strains of RRV expressing the rhesus monkey-derived anti-SIV monoclonal antibodies 4L6 and 5L7 and compared the RRV-mediated in vivo delivery of these antibodies in rhesus monkeys with previous studies that utilized intramuscular delivery with an adeno-associated virus (AAV) vector. Recombinant RRV-4L6 and RRV-5L7 were both shown to stably produce the antibodies in persistently infected B-cell lines in culture. Two RRV-negative rhesus monkeys were experimentally infected with recombinant RRV-4L6 and two with recombinant RRV-5L7. Following infection, the appearance of the delivered antibody was readily detected in all four animals. However, the levels of the delivered antibody were considerably lower than what has been typically observed following intramuscular AAV delivery. Furthermore, three of the four monkeys had an antibody response to the delivered antibody as had been observed previously with intramuscular AAV delivery of these same antibodies. We conclude that this recombinant herpesvirus has no inherent advantage over AAV for delivery of potentially therapeutic monoclonal antibodies in a rhesus monkey model.
INTRODUCTION
Discovery of effective vaccine approaches for the prevention of HIV infection has remained elusive and antiviral drug therapies, while effective at suppressing viral replication, are not a cure. Alternative strategies are becoming increasingly worthy of serious exploration. Delivery of monoclonal antibodies (mAbs) with potent neutralizing activity against a broad range of isolates is one promising approach that can be considered both for the prevention and for the treatment of HIV infection. 1 This approach is made possible by an incredible array of such mAbs that have been isolated and characterized over the last several years. [2] [3] [4] [5] [6] [7] [8] [9] Passive administration of such antibodies to HIV-infected people has been shown to be safe and has effectively lowered viral loads for as long as therapeutic concentrations of mAbs have been maintained. [10] [11] [12] Passive administration of such antibodies to monkeys has also been shown to prevent infection following subsequent challenge with simian-human immunodeficiency virus. 13, 14 However, worldwide use of such antibody-driven approaches will likely depend heavily on the ability to achieve long-term delivery following a single administration. Several groups including our own have so far used intramuscular inoculation of recombinant adeno-associated virus (AAV) vector to deliver antibodies or antibody-like molecules against HIV or the simian immunodeficiency virus (SIV) to monkeys. [15] [16] [17] [18] [19] The only protein product derived from the AAV vector comes from the transgene that is placed into it; as long as that protein product is not viewed as foreign, protein expression may continue for years following intramuscular administration. 17, 20, 21 Muscle cells turn over very little if at all, helping to ensure the long-term delivery. At least three of the monkey studies have suffered from strong antibody responses of the host to the delivered antibody that severely limited the concentrations of the mAbs that could be achieved. 15, 17, 18 To what extent unnatural expression of the mAbs in muscle cells plays a role in these anti-anti responses is not clear.
Given these and other issues, alternate vector systems for achieving long-term delivery of mAbs are worthy of consideration. Herpesviruses have large DNA genomes, can accommodate large amounts of inserted genetic information and most importantly persist for the lifetime of the infected host. While herpesviruses are known to become latent to one extent or another, the lifelong persistence of anti-herpesviral antibodies at high levels for the lifetime of the persistently infected host is clear evidence for lifelong expression of viral-encoded proteins. Furthermore, Hadinoto et al. 22 have demonstrated the continuous shedding of Epstein-Barr virus virions into saliva over the course of years as the natural course of Epstein-Barr virus infection. The gamma-2 herpesvirus of rhesus monkeys, rhesus monkey rhadinovirus (RRV), is a close monkey homolog of the human Kaposi sarcoma herpesvirus, the human herpesvirus 8. [23] [24] [25] A principle site of persistence of RRV is the B cell, the same cell type that naturally produces antibodies in vivo. [26] [27] [28] The Desrosiers lab has developed a genetic system for RRV and used recombinant RRV to achieve long-term delivery of SIV antigens, persistent effector memory responses to these antigens and antibody responses against the SIV envelope protein in rhesus monkeys. [29] [30] [31] In the study described here, we evaluated the use of recombinant RRV for its capacity to deliver the anti-SIV mAbs 4L6 and 5L7 in four rhesus macaques.
RESULTS

Expression of 4L6 and 5L7 in cell culture
Recombinant RRVs encoding either 4L6 or 5L7 in authentic rhesus immunoglobulin G1 (IgG1) form were constructed (Figure 1 ). Rhesus fibroblasts (RF) permissive for RRV replication and an immortalized rhesus B-cell line (LCL211-98) were infected with these recombinants and cell culture supernatants were harvested and analyzed for production of the antibodies (Figure 2) . RRV has been shown to establish long-term persistent infection in the LCL211-98 B-cell line, with only a small minority of cells activated to the lytic cycle at any one time. 32 Both, 4L6 and 5L7 could be readily detected in the cell culture supernatant of infected RF cells by immunoblotting using appropriate mAbs (Figure 2a) . Furthermore, an experiment with recombinant RRV-infected RF cells showed an increase of antibody levels over time reaching concentrations of 11-13 μg ml − 1 at the time of complete virusinduced lysis (Figure 2b ). Stable expression of 4L6 and 5L7 was observed in B-cell lines over the course of 28 days, evidenced by antigen capture assays for 4L6 or 5L7. Maximal concentrations of 4L6 and 5L7 of~300-400 ng ml − 1 from the B-cell line were observed 21-28 days following the recombinant RRV infection (Figure 2c ).
Expression of 4L6 and 5L7 in rhesus macaques Recombinant RRV was used as a gene transfer vector to mediate the delivery of the monoclonal anti-SIV antibodies 4L6 and 5L7 to RRV-negative rhesus macaques (Table 1) . Enzyme-linked immunosorbent assays (ELISA) plates were coated with gp120 and used to quantitate the concentrations of delivered antibody in the sera of the research animals using an antigen capture assay. After 6 weeks, sera of both recombinant RRV-4L6 recipients showed detectable 4L6 levels. Antibody peaks of 423 ng ml − 1 (r11103) and 477 ng ml − 1 (r10090) were observed by week 12 post inoculation ( Figure 3a ). After these observed peaks, 4L6 levels dropped considerably; however, levels of 79 ng ml − 1 (r11103) and 67 ng ml − 1 (r10090) were still observed by week 49 after recombinant RRV administration (Figure 3a ). Similar kinetics were overserved for the monkeys that received recombinant RRV expressing 5L7 (Figure 3b ). After no detectable 5L7 for the first 4 weeks post inoculation, 5L7 was readily detected by week 6 in the sera of both animals. Peak antibody levels of 145 ng ml − 1 (r10074) and 112 ng ml − 1 (r12082) were achieved by week 12 and week 8 post recombinant RRV inoculation, respectively. Similar to the 4L6 group, these peaks were followed by declines in antibody levels. By week 49 post inoculation, 5L7 concentrations of 24 ng ml − 1 (r10074) and 3 ng ml − 1 (r12082) were still detectable.
Host anti-antibody responses To examine whether RRV-mediated delivery of the mAbs led to the elicitation of host anti-antibodies, ELISAs were performed with homologous purified protein used to coat ELISA plates. Host antibodies directed to 4L6 became detectable 3-4 weeks after the administration of the recombinant RRV-4L6 ( Figure 3c ). In fact, anti-4L6 responses were first detectable even before 4L6 itself was detected. These anti-anti responses of the host were maintained and still readily detectable by week 49. Host antibody responses to Figure 1 . Position of the 4L6 or 5L7 transgene cassette in recombinant RRV. The expression cassette for either 4L6 or 5L7 was inserted between the left terminal repeats (TR) and the first open reading frame R1 of RRV. To ensure an equimolar delivery of heavy and light chains into the cells, both polypeptides are expressed from one coding sequence using a F2A self-processing peptide from the foot-and-mouth disease virus. The expression cassette consists of the CMV promoter (pCMV), the SV40 intron, the heavy and light chain coding sequencesboth preceded by a signal peptide (SP)-separated by F2A, the amino-acid spacer sequence SGSG, the Furin peptide, the cis-acting element (WPRE) derived from the woodchuck hepatitis virus, and the SV40 polyA signal. In this approach, heavy and light chain are subsequently translated from a single mRNA. During SP-mediated elongation into the ER lumen, the polyprotein sequence undergoes self-cleavage through a ribosomal 'skip' mechanism upon reaching the amino-acid residues of the F2A peptide. Then, the two polypeptide chains are folded, glycosylated and assembled in the lumen of the ER. Additional modifications in the Golgi lead to a removal of any F2A peptide residues, which is induced by Furin cleavage. Furthermore, carboxypeptidases then remove redundant Furin residues. Ultimately, full-length, authentic IgGs get secreted.
5L7 were weaker and readily detected in only one of the two monkeys that received recombinant RRV-5L7 (Figure 3d ). In the one of two monkeys with readily detected antibody responses to 5L7, the anti-antis again persisted for the 49 weeks of measurement.
Host anti-RRV responses We also monitored the development of antibodies to RRV antigens as a consequence of the recombinant RRV infection. As expected, anti-RRV antibodies emerged and persisted for the 49 weeks of measurement consistent with the expected long-term persistent infection caused by this herpesvirus (Figure 4 ).
DISCUSSION
In this study, we have shown that inoculation with persistent, replication-competent recombinant RRV expressing authentic rhesus IgG1 forms of the anti-SIV mAbs 4L6 and 5L7 resulted in readily detectable antibody levels in the sera of all four research animals (Figures 3a and b) . However, the levels were drastically lower in comparison to what was observed in the study conducted by Fuchs et al. 17 where recombinant AAV-mediated delivery of 4L6 and 5L7 lead to antibody concentrations between 1 and 270 μg ml − 1 . Although slightly delayed, the overall kinetics of antibodies delivered by recombinant RRV were comparable to recombinant AAV-delivered 4L6 where initial peaks postrecombinant-AAV inoculation were followed by a strong decline in 4L6 IgG1 levels in the vast majority of the research animals.
Similar to observations in recombinant AAV studies, the rapid and severe decline of delivered antibody levels in the research animals that received a recombinant RRV expressing either 4L6 or 5L7 was associated with a strong anti-antibody responses (Figures 3c and d) . 17, 18, 33 Comparable to our previous studies using AAV, 17, 33 the anti-4L6 responses in our present study with recombinant RRV were higher than the measured responses against 5L7. Furthermore, both recombinant RRV-4L6 recipients showed clear anti-antibody responses, whereas only one of the two recombinant RRV-5L7 recipients exhibited measurable antiantibodies; this also reflects the AAV results where anti-anti responses were consistently observed in six of six monkeys with 4L6 delivery but only in three of six monkeys with 5L7 delivery. 17 The establishment of RRV latency could be an additional factor leading to an decrease in delivered antibody concentrations following peak levels 8-12 weeks after initial infection. 26 During latency, only a few genes are actively expressed and it is feasible that expression of any introduced transgene may be low during latency as well. 34, 35 On the basis of our findings, we conclude that the use of the recombinant herpesvirus RRV for delivery of mAbs does not provide any advantage over the use of recombinant AAV in our rhesus monkey model system. Targeting antibody expression to B cells did not circumvent the problem of host antibody responses to the delivered antibody. Our findings indicate that the anti-anti problem will likely be a major impediment to the use of viral vectors to deliver anti-HIV antibodies for the treatment or Figure 2 . Expression of antibodies in rhesus fibroblast and rhesus B-cell line cultures after infection with recombinant RRV. (a) Rhesus fibroblast cell line culture supernatants were harvested. Samples were prepared in a non-reducing sample buffer and separated by SDSpolyacrylamide gel electrophoresis under non-reducing conditions, the separated proteins were transferred to a polyvinylidene difluoride membrane, and subsequently tested with HRP-conjugated anti-rhesus IgG1 antibodies. rRRV-4L6 represents cell culture supernatant from RF cells infected with recombinant RRV-4L6 and rRRV-5L7 represents cell culture supernatant from RF cells infected with recombinant RRV-5L7. (b) Rhesus fibroblast cell lines were infected with recombinant RRV and the cell culture supernatants were analyzed for the concentration of 4L6 or 5L7, respectively, via an ELISA using recombinant gp120 to coat the ELISA plates. The samples were probed with a HRP-conjugated anti-rhesus IgG antibody. (c) Immortalized rhesus B-lymphocyte cell lines were infected with recombinant RRV and the cell culture supernatants were analyzed for the concentration of 4L6 or 5L7, respectively via an ELISA using recombinant gp120 to coat the ELISA plates. The samples were probed with a HRP-conjugated anti-rhesus IgG antibody. prevention of HIV infection in humans. The situation is particularly problematic since the anti-HIV antibodies with potent neutralizing activity against a broad range of HIV isolates that one wants to deliver are for the most part extremely divergent from germline. 36, 37 The data of Martinez-Navio et al. 33 indicate that the magnitude of the anti-anti response is directly proportional to the distance from the germline of the antibody being delivered.
MATERIALS AND METHODS
Cell culture
Cells from a rhesus monkey fibroblast cell line (RF, NEPRC, Southborough, MA, USA) were cultured and maintained in Dulbecco's modified Eagle medium (DMEM, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 20% fetal calf serum (Thermo Fisher Scientific), and primocin (InvivoGen, San Diego, CA, USA). The Epstein-Barr virus-immortalized rhesus B-cell line LCL211-98 was cultured and maintained in RPMI media (Thermo Fisher Scientific) supplemented with 20% fetal calf serum (Thermo Fisher Scientific), and primocin (InvivoGen). 38 Anti-SIV antibodies 4L6 and 5L7 characteristics The generation of sequences encoding for 4L6 and 5L7 in authentic rhesus IgG1 form was performed as previously described. 17 Generation of recombinant rhesus monkey rhadinovirus Recombinant RRVs expressing either 4L6 or 5L7 were made by co-transfection of multiple overlapping cosmids as previously described. 30 Recombinant RRV-infected RF culture supernatants were harvested, spun down twice at 2000 r.c.f. for 5 min to remove any cell debris, and resulting virus titers were measured via quantitative real-time PCR using a RRV latency-associated nuclear antigen specific primer set. The reaction was completed using the TaqMan Fast Virus 1-Step Master Mix (Thermo Fisher Scientific) in a Real-time PCR Thermocycler (Thermo Fisher Scientific); Forward primer; 5′-ACCGCCTGTTGCGTGTTA-3′, reverse primer; 5′-CAAT CGCCAACGCCTCAA-3′, reporter; FAM-5′-CAGGCCCCATCCCC-3′. FAM-5′-CAGGCCCCATCCCC-3′.
Expression of 4L6 and 5L7 in rhesus monkey fibroblasts For immunoblotting experiments, a total of 250 000 RF cells were seeded into each well of a six-well plate. The following day, cells were infected with 50 μl of a stock of recombinant RRV containing 1 × 10 9 genome copies per ml expressing either 4L6 or 5L7. Cells were kept in culture 6 days before harvesting the cell culture Figure 3 . Levels of recombinant RRV-delivered antibodies and host anti-antibody response in rhesus macaques. Sera of four rRRV-inoculated rhesus macaques were tested for the presence of (a) 4L6 or (b) 5L7 via an ELISA using recombinant gp120 to coat the ELISA plates. The samples were probed with a HRP-conjugated anti-rhesus IgG antibody. The obtained sera were also tested for the presence of antibodies against (c) 4L6 or (d) 5L7 via an ELISA using homologous purified protein to coat the ELISA plates. The samples were probed with a HRP-conjugated anti-lambda antibody. supernatant when cells were exhibiting advanced cytopathic effect.
For antibody measurements experiments, 1 million RF cells were seeded into a T25 cell culture vessel. The following day, cells were infected with 100 μl of a stock of recombinant RRV containing 1 × 10 9 genome copies per ml expressing either 4L6 or 5L7. Cells were kept in culture for 8 days until all the cells were lysed. Daily, 1 ml of cell culture supernatant was harvested and replaced by 1 ml of fresh RPMI media supplemented with 20% fetal calf serum.
Expression of 4L6 and 5L7 in immortalized rhesus B-lymphocytes One million LCL211-98 cells were seeded into a T25 cell culture vessel. The following day, cells were infected with 100 μl of a stock of recombinant RRV containing 1 × 10 9 genome copies per ml expressing either 4L6 or 5L7. Cells were arbitrarily diluted 1:6 in fresh RPMI media supplemented with 20% fetal calf serum on day 2, 7, 14 and 21, and were kept in culture for a total of 28 days. Prior to each dilution 1 ml of cell culture supernatant was harvested.
Immunoblotting Cell culture supernatants were harvested and spun down at 16 000 r.c.f. for 15 min. After centrifugation, supernatants were transferred into new tubes, protein levels were measured and the samples were normalized using a bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Each sample was mixed with an equal volume of 4 × non-reducing LDS sample buffer (Thermo Fisher Scientific). Subsequently, samples were incubated at 97°C for 5 min and separated by SDS-polyacrylamide gel electrophoresis under non-reducing conditions. The proteins from the gels were transferred to a polyvinylidene difluoride membrane (BioRad, Hercules, CA, USA) and subjected to immunoblotting. Briefly, the membranes were blocked with phosphate-buffered saline (PBS) containing 5% skim milk and incubated with a horseradish peroxidase (HRP)-conjugated anti-rhesus IgG antibody (SouthernBiotech, Birmingham, AL, USA). Chemiluminescence was detected with a LAS4000 mini system (GE Healthcare Systems, Chicago, IL, USA) using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher Scientific).
Enzyme-linked immunosorbent assays Since both 4L6 and 5L7 are capable of binding the SIVmac239 envelope glycoprotein, LCL211-98 cell culture supernatants and sera of four research animals were tested for the presence of 4L6 and 5L7. ELISA plates were coated with recombinant gp120 of SIVmac239 (Immune Technology, New York, NY, USA) for 1 h at 37°C and the plates were subsequently washed with PBS Tween20 (Sigma-Aldrich, St Louis, MO, USA). Afterwards, the plates were blocked with 5% non-fat dry milk in PBS (Bio-Rad). The LCL211-98 samples and the macaque sera were serially diluted 1:3 in blocking buffer and applied to the test plate. Samples were incubated for 1 h at 37°C and the plates washed again. Then a HRP-conjugated goat anti-rhesus IgG H+L (SouthernBiotech) was added and the plates incubated for 1 h at 37°C. Sequentially, TMB substrate (SouthernBiotech) and stop solutions (SouthernBiotech) were added. The absorbance at 450 nm per well was measured in a microplate reader (PerkinElmer, Waltham, MA, USA).
Similarly, the sera of all four research animals were tested for the presence of anti-antibodies against 4L6 or 5L7 by coating the ELISA plates with homologous purified protein and probing the samples in a 1:20 dilution with a HRP-conjugated anti-lambda antibody (SouthernBiotech). 33 In addition, all sera obtained from the research animals were analyzed for the presence of anti-RRV responses by coating the ELISA plate with purified RRV lysate and subsequent probing of the 1:20 diluted samples with a HRP-conjugated anti-rhesus IgG antibody (SouthernBiotech).
Research animals Four rhesus macaques of Indian origin (Macaca mulatta) were enrolled in this study, and all were housed at the Wisconsin National Primate Research Center (WNPRC). The animals were cared for in accordance with the guidelines of the Weatherall Report under a protocol approved by the University of Wisconsin Graduate School Animal Care and Use Committee. All animals were under anesthesia during recombinant RRV inoculation and during subsequent blood draws.
Recombinant RRV inoculation The recombinant RRV stock expressing 4L6 was diluted to a total of 1 × 10 9 genome copies per ml in PBS and 1 ml of the rRRV-4L6 dilution was administered to two rhesus macaques intravenously. Similarly, the 5L7 expressing recombinant RRV was diluted to a total of 1 × 10 9 genome copies per ml in PBS, and 1 ml was administered to two other rhesus macaques intravenously.
